Italia markets close in 3 hours 17 minutes

FTSE MIB
34.311,29
-348,26(-1,00%)
Dow Jones
38.852,86
-216,74(-0,55%)
Nasdaq
17.019,88
+99,08(+0,59%)
Nikkei 225
38.556,87
-298,50(-0,77%)
Petrolio
80,41
+0,58(+0,73%)
Bitcoin EUR
62.441,73
-375,65(-0,60%)

Philogen S.p.A. (PHIL.MI)

Milan - Milan Prezzo differito. Valuta in EUR.

Aggiungi a watchlist

20,90

+0,40

(+1,95%)

In data: 01:55PM CEST. Mercato aperto.

Capitalizzazione	842,053M
Beta (mensile su 5 anni)	0,12
Rapporto PE (ttm)	N/D
EPS (ttm)	-0,15
Prossima data utili	N/D
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	17,00

Tutte

GlobeNewswire
Nidlegy™ Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma
Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in a Phase III randomized clinical trial The results will be presented at an upcoming intern